CytoMed Therapeutics shares are trading higher after the company announced that its subsidiary, IPSC Depository, acquired the license and certain assets of Cellsafe International for approximately $490,000 to be funded from internal cash resources.
Portfolio Pulse from Benzinga Newsdesk
CytoMed Therapeutics shares are trading higher after its subsidiary, IPSC Depository, acquired the license and certain assets of Cellsafe International for approximately $490,000, funded from internal cash resources.
July 17, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CytoMed Therapeutics' stock is trading higher following the acquisition of Cellsafe International's assets by its subsidiary, IPSC Depository, for $490,000.
The acquisition of Cellsafe International's assets by CytoMed's subsidiary is likely to be seen positively by investors, as it indicates strategic growth and utilization of internal cash resources. This has led to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100